LINCOLN PHARMA LTD (LINCOLN) financials

LINCOLN PHARMA LTD (LINCOLN) NSE/BSE financials on Fincrux: quarterly results, profit and loss, cash flow, balance sheet, ratios, and shareholding.

Incorporated in 1979, Lincoln Pharmaceuticals Ltd is in the business of manufacturing and trading of pharmaceutical products[1]

Market Cap: ₹1,098Cr.
Current Price: ₹546
Stock P/E: 11.4
ROE: 12.0%
ROCE: 16.0%
Book Value: ₹378
Dividend Yield: 0.33%
52W High / Low: ₹770/440

In Jun 2026, LINCOLN PHARMA LTD (LINCOLN) reported sales ₹177 Cr and net profit ₹36 Cr.

Annual TTM: sales ₹694 Cr, net profit ₹96 Cr.

Shareholding: Promoters 49.78% (Jun 2026), FIIs 4.60% (Jun 2026), DIIs 0.27% (Jun 2026), Public 45.36% (Jun 2026), No. of Shareholders 29,396% (Jun 2026).

LINCOLN quarterly results (₹ Cr.)
Category	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Sales	161	147	168	154	163	166	187	177
Expenses	133	123	141	130	138	143	162	150
Operating Profit	28	24	27	24	25	24	25	27
OPM %	18%	16%	16%	15%	16%	14%	13%	15%
Other Income	10	9	-7	15	7	15	-4	24
Interest	0	1	0	0	0	0	0	0
Depreciation	3	3	3	3	4	4	4	4
Profit before tax	35	29	16	35	29	35	17	48
Tax %	24%	28%	29%	22%	31%	18%	30%	24%
Net Profit	26	21	12	28	20	29	12	36
EPS in Rs	13.15	10.37	5.78	13.82	9.98	14.28	5.81	18.09
Raw PDF	—	—	—	—	—	—	—	—

LINCOLN profit and loss (₹ Cr.)
Category	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026	TTM
Sales	376	423	472	510	581	623	671	694
Expenses	317	336	376	421	480	522	573	593
Operating Profit	60	87	96	90	100	102	98	101
OPM %	16%	21%	20%	18%	17%	16%	15%	15%
Other Income	12	6	10	22	34	22	33	42
Interest	2	2	1	2	1	2	1	1
Depreciation	5	8	8	9	11	13	14	15
Profit before tax	64	84	96	100	122	109	116	128
Tax %	23%	26%	28%	27%	24%	25%	24%	—
Net Profit	50	62	69	73	93	82	88	96
EPS in Rs	24.78	31.12	34.62	36.40	46.58	41.11	43.88	48.16
Dividend Payout %	6%	5%	4%	4%	4%	4%	0%	—

LINCOLN balance sheet (₹ Cr.)
Category	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Equity Capital	20	20	20	20	20	20	20	20
Reserves	243	284	346	413	482	573	652	738
Borrowings	34	5	1	2	2	1	0	4
Other Liabilities	51	58	85	99	83	106	125	128
Total Liabilities	347	367	452	534	587	700	797	890
Fixed Assets	88	91	111	132	151	179	182	191
CWIP	2	0	2	16	7	3	4	5
Investments	46	60	81	97	91	139	174	209
Other Assets	211	216	259	289	339	378	437	485
Total Assets	347	367	452	534	587	700	797	890

LINCOLN cash flows (₹ Cr.)
Category	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Cash from Operating Activity	51	71	69	76	39	63	93	106
Cash from Investing Activity	-22	-29	-64	-78	-37	-57	-79	-98
Cash from Financing Activity	-30	-38	-6	-3	-4	-5	-6	0
Net Cash Flow	-1	4	-1	-4	-2	1	8	8
Free Cash Flow	40	65	61	31	26	24	74	82
CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit	112%	142%	102%	104%	77%	89%	117%	135%

LINCOLN shareholding pattern (%)
Category	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Promoters	49.78%	49.78%	49.78%	49.78%	49.78%	49.78%	49.78%	49.78%
FIIs	5.19%	5.16%	5.00%	5.13%	4.73%	4.70%	5.20%	4.60%
DIIs	0.00%	0.00%	0.00%	0.01%	0.01%	0.01%	1.08%	0.27%
Public	45.04%	45.07%	45.23%	45.08%	45.49%	45.51%	43.94%	45.36%
No. of Shareholders	31,330	31,848	31,867	31,784	32,370	31,026	28,303	29,396

LINCOLN key ratios
Category	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Debtor Days	117	88	97	89	97	101	97	87
Inventory Days	61	73	86	121	106	101	99	94
Days Payable	74	82	105	119	77	95	106	99
Cash Conversion Cycle	104	80	78	91	126	108	89	82
Working Capital Days	96	111	120	114	121	121	116	126
ROCE %	22%	22%	25%	24%	22%	22%	17%	16%

LINCOLNUpdated 16 Oct 2026, 20:21

Lincoln Pharma Ltd

LINCOLNUpdated 16 Oct 2026, 20:21

Market Cap

₹1,098Cr.

Current Price

₹546

High / Low

₹770/440

Stock P/E

11.4

ROE12.0%

ROCE16.0%

Book Value₹378

Face Value₹10.0

Dividend Yield0.33%

About

Incorporated in 1979, Lincoln Pharmaceuticals Ltd is in the business of manufacturing and trading of pharmaceutical products[1]

Quarterly results

Last reported quarters₹ Cr.

Quarter	Sales	Interest	Expenses	Other Income	Depreciation	Profit Before Tax	Tax	Net Profit	EPS (₹)
Jun 2023	136	0	115	8	3	25	25	19	9.49
Sep 2023	156	0	125	9	3	37	25	28	13.8
Dec 2023	146	0	117	11	3	38	26	28	14
Mar 2024	142	0	124	7	3	22	16	19	9.29
Jun 2024	147	0	125	10	3	29	20	24	11.82
Sep 2024	161	0	133	10	3	35	24	26	13.15
Dec 2024	147	1	123	9	3	29	28	21	10.37
Mar 2025	168	0	141	-7	3	16	29	12	5.78
Jun 2025	154	0	130	15	3	35	22	28	13.82
Sep 2025	163	0	138	7	4	29	31	20	9.98
Dec 2025	166	0	143	15	4	35	18	29	14.28
Mar 2026	187	0	162	-4	4	17	30	12	5.81
Jun 2026	177	0	150	24	4	48	24	36	18.09

Profit & loss

Annual statement₹ Cr.

Year	Sales	Interest	Expenses	Other Income	Depreciation	Profit Before Tax	Tax	Net Profit	EPS (₹)
Mar 2015	223	6	200	5	3	19	23	15	9.06
Mar 2016	311	6	278	6	3	30	28	22	13.33
Mar 2017	304	5	261	2	4	36	23	27	13.7
Mar 2018	325	4	279	6	4	43	24	33	16.38
Mar 2019	353	4	292	6	5	58	20	47	23.32
Mar 2020	376	2	317	12	5	64	23	50	24.78
Mar 2021	423	2	336	6	8	84	26	62	31.12
Mar 2022	472	1	376	10	8	96	28	69	34.62
Mar 2023	510	2	421	22	9	100	27	73	36.4
Mar 2024	581	1	480	34	11	122	24	93	46.58
Mar 2025	623	2	522	22	13	109	25	82	41.11
Mar 2026	671	1	573	33	14	116	24	88	43.88
TTM	694	1	593	42	15	128	—	96	48.16

Shareholding pattern

As of Jun 2026%

Holder	Share
Promoters	49.78%
FIIs	4.6%
DIIs	0.27%
Public	45.36%

Shareholding trend

Ownership over time%

Quarter	Promoters	FIIs	DIIs	Government	Public
Sep 2023	50.53%	2.59%	0%	—	46.87%
Dec 2023	49.81%	3.22%	0.06%	—	46.92%
Mar 2024	49.54%	3.93%	0.05%	—	46.49%
Jun 2024	49.78%	3.95%	0.04%	—	46.24%
Sep 2024	49.78%	5.19%	0%	—	45.04%
Dec 2024	49.78%	5.16%	0%	—	45.07%
Mar 2025	49.78%	5%	0%	—	45.23%
Jun 2025	49.78%	5.13%	0.01%	—	45.08%
Sep 2025	49.78%	4.73%	0.01%	—	45.49%
Dec 2025	49.78%	4.7%	0.01%	—	45.51%
Mar 2026	49.78%	5.2%	1.08%	—	43.94%
Jun 2026	49.78%	4.6%	0.27%	—	45.36%

Balance sheet

Assets & liabilities₹ Cr.

Period	Equity Capital	Reserves	Borrowings	Other Liabilities	Total Liabilities	Fixed Assets	CWIP	Investments	Other Assets	Total Assets
Mar 2015	16	95	48	32	192	33	3	13	143	192
Mar 2016	16	122	61	43	242	63	3	20	156	242
Mar 2017	20	170	53	39	282	68	7	36	171	282
Mar 2018	20	200	56	50	326	83	0	39	204	326
Mar 2019	20	243	34	51	347	88	2	46	211	347
Mar 2020	20	284	5	58	367	91	0	60	216	367
Mar 2021	20	346	1	85	452	111	2	81	259	452
Mar 2022	20	413	2	99	534	132	16	97	289	534
Mar 2023	20	482	2	83	587	151	7	91	339	587
Mar 2024	20	573	1	106	700	179	3	139	378	700
Mar 2025	20	652	0	125	797	182	4	174	437	797
Mar 2026	20	738	4	128	890	191	5	209	485	890

Cash flows

Operating, investing & financing₹ Cr.

Period	Operating	Investing	Financing	Net cash flow
Mar 2015	9	-5	-5	-1
Mar 2016	29	-40	11	0
Mar 2017	18	-26	8	0
Mar 2018	21	-14	-4	4
Mar 2019	51	-22	-30	-1
Mar 2020	71	-29	-38	4
Mar 2021	69	-64	-6	-1
Mar 2022	76	-78	-3	-4
Mar 2023	39	-37	-4	-2
Mar 2024	63	-57	-5	1
Mar 2025	93	-79	-6	8
Mar 2026	106	-98	0	8

Key ratios

Historical financial ratios

Category	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Debtor Days	135	88	95	108	117	88	97	89	97	101	97	87
Inventory Days	49	44	67	78	61	73	86	121	106	101	99	94
Days Payable	34	37	53	75	74	82	105	119	77	95	106	99
Cash Conversion Cycle	150	96	110	111	104	80	78	91	126	108	89	82
Working Capital Days	83	50	74	90	96	111	120	114	121	121	116	126
ROCE %	16%	20%	19%	18%	22%	22%	25%	24%	22%	22%	17%	16%

Frequently asked questions

Quick answers about this company's financials on Fincrux

What is the market cap of LINCOLN PHARMA LTD (LINCOLN)?

The reported market capitalisation for LINCOLN PHARMA LTD (LINCOLN) is ₹1,098Cr. on Fincrux. Figures may update with market data and filings.

What is the current share price of LINCOLN?

The current price shown for LINCOLN PHARMA LTD (LINCOLN) on Fincrux is ₹546 with a 52-week high/low of ₹770/440.

What is the P/E ratio of LINCOLN PHARMA LTD (LINCOLN)?

The stock P/E for LINCOLN PHARMA LTD (LINCOLN) is 11.4 on Fincrux, with ROE at 12.0% and ROCE at 16.0%.

What were LINCOLN latest quarterly results?

For Jun 2026, LINCOLN PHARMA LTD (LINCOLN) reported sales ₹177 Cr and net profit ₹36 Cr (figures in ₹ crore unless noted).

What are LINCOLN annual sales and net profit?

For TTM, LINCOLN PHARMA LTD (LINCOLN) shows sales of ₹694 Cr and net profit of ₹96 Cr on the Fincrux profit & loss statement.

Who owns LINCOLN PHARMA LTD (LINCOLN)?

Latest shareholding for LINCOLN PHARMA LTD (LINCOLN) on Fincrux: Promoters 49.78% (Jun 2026), FIIs 4.60% (Jun 2026), DIIs 0.27% (Jun 2026), Public 45.36% (Jun 2026), No. of Shareholders 29,396% (Jun 2026).

Where can I find LINCOLN PHARMA LTD (LINCOLN) financials?

LINCOLN PHARMA LTD (LINCOLN) financials on Fincrux include quarterly results, profit and loss, cash flow, balance sheet, key ratios, and shareholding patterns for NSE/BSE research.

Does Fincrux show LINCOLN balance sheet and cash flow?

Yes. The LINCOLN PHARMA LTD (LINCOLN) page on Fincrux includes balance sheet, cash flow statements, historical ratios, and ownership trends alongside quarterly and annual results.

Figures in ₹ crore unless noted. Data sourced for research and may lag filings.

Last updated 16 October 2026 at 20:21